Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Portal Hypertension01:22

Portal Hypertension

Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
Liver Histology01:27

Liver Histology

The microscopic anatomy of the liver is a complex and intricate system that comprises numerous structural units known as liver lobules, each of which is comparable in size to a sesame seed. These hexagonal structures consist of plates of liver cells or hepatocytes, which are characterized by their versatility and abundance of cellular apparatus like rough and smooth ER, Golgi apparatus, peroxisomes, and mitochondria.
Hepatocytes perform a variety of essential functions. They secrete...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

In Vitro TLR4 Stimulating Bioactivities of Amylase/Trypsin-Inhibitors from Wheat (<i>Triticum aestivum</i> L.) Bred from 1891 to 2010.

Foods (Basel, Switzerland)·2026
Same author

Erratum to 'Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis' [J Hepatol 83 (2025) 239-257].

Journal of hepatology·2026
Same author

Upcoming Treatments in Celiac Disease: From Luminal Enzymes to Oral Immune Tolerance.

United European gastroenterology journal·2026
Same author

Therapeutic TG2 inhibition reverses systemic multiomic dysregulation in celiac disease.

BMC medicine·2026
Same author

Sex-related differences in cardiovascular inflammation and metabolomics in a humanized transgenic mouse model of celiac disease.

Scientific reports·2026
Same author

ECM1 produced by hepatic stellate cells serves as a gatekeeper of liver homeostasis in hepatic fibrosis.

Hepatology (Baltimore, Md.)·2026

関連する実験動画

肝硬変 (肝硬変) について

Detlef Schuppan1, Nezam H Afdhal

  • 1Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. dschuppa@bidmc.harvard.edu

Lancet (London, England)
|March 11, 2008
PubMed
まとめ
この要約は機械生成です。

肝硬変という重篤な肝臓疾患は,その進行と合併症を理解する進歩により,より良く管理されています. 新しい治療法は,肝臓疾患を停止または逆転させ,移植を超えて患者のアウトカムを改善することを目的としています.

関連する実験動画

科学分野:

  • 肝臓病理学 肝臓病理学
  • 内科内科は,内科の内科である.
  • 病理生理学 病理生理学とは

背景:

  • 肝硬変は,慢性的な損傷による肝臓の痕で特徴づけられ,ポータル高血圧と末期肝臓疾患につながる.
  • 最近の科学的な理解は,肝硬変の患者の管理,生活の質,生存を向上させました.
  • 肝臓移植は一部の人々にとって治療的ですが,肝臓疾患の進行を停止または逆転させるための新しい薬理学的アプローチが生まれています.

研究 の 目的:

  • 肝硬変の診断,合併症,および管理に関する包括的な概要を提供します.
  • 肝硬変の理解と治療における最近の臨床的,科学的進歩を強調する.
  • 肝疾患の新薬学的治療法の開発について議論する.

主な方法:

  • 肝硬変の病理生理学と自然史に関する現在の文献のレビュー.
  • 新興の肝硬変治療のための最近の臨床試験データの分析.
  • 診断と管理戦略に関する専門知識の統合.

主要な成果:

  • 肝硬変の合併症のより良い管理を通じて,患者のアウトカムと寿命の改善.
  • 肝繊維症を停止または逆転させる可能性を有する薬理学的薬剤の開発.
  • 肝臓移植を特定の患者のための重要な治療法として特定すること.

結論:

  • 肝硬変の理解における進歩は,患者のケアと予後を改善しています.
  • 薬理学的治療は,潜在的に肝臓の損傷を逆転させる可能性のある地平線にあります.
  • 移植や新しい治療法を含む多面的なアプローチは,進行した肝疾患の管理に不可欠です.